Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: July 2021 (Specific date: July 6, 2021)
Headquarters: Melbourne, VIC, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document serves as a regulatory notice rather than a financial results report.
Material Changes
No material financial changes or comparative period data are disclosed in this specific filing text.
Guidance, Outlook, and Risks
Management Commentary: None provided in this excerpt.
Regulatory Action: The filing incorporates a "Notice under section 708A (5) of Corporation Act" (Exhibit 99.1).
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-251647, 333-249311, 333-231417, 333-250076).
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (Notice under section 708A (5) of Corporation Act) to understand the specific corporate action triggering this filing.
- Verify the status of the referenced Form S-8 and Form F-3 registration statements for details on equity offerings or employee compensation plans.
- Confirm the company's current cash runway and burn rate in the most recent audited financial statements, as this 6-K does not contain financial data.